Lexicon Pharmaceuticals (LXRX) Short term Debt (2010 - 2025)

Lexicon Pharmaceuticals' (LXRX) quarterly Short term Debt came in at $4.6 million in Q4 2025, down 89.07% on a QoQ basis from $42.1 million in Q1 2025.

Lexicon Pharmaceuticals (LXRX) Short term Debt (2010 - 2025) Analysis & Trends

Lexicon Pharmaceuticals (LXRX) has 13 years of Short term Debt data on file, last reported at $4.6 million in Q4 2025.

  • On a quarterly basis, Short term Debt changed N/A year-over-year to $4.6 million in Q4 2025; TTM through Dec 2025 was $4.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $4.6 million, changed N/A from the prior year.
  • Short term Debt for Q4 2025 stood at $4.6 million, down from $42.1 million in the prior quarter.
  • Over the last five years, Short term Debt for LXRX reached as high as $42.1 million in Q1 2025 and fell as low as $4.6 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Lexicon Pharmaceuticals 979.13 Mn 808.47 Mn 20.99 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 4.60 Mn
Mar 31, 2025 42.06 Mn
Sep 30, 2021 11.69 Mn
Jun 30, 2021 11.68 Mn
Mar 31, 2021 11.66 Mn
Dec 31, 2020 11.65 Mn
Sep 30, 2020 8.69 Mn
Jun 30, 2020 10.46 Mn
Mar 31, 2020 10.73 Mn
Dec 31, 2019 11.01 Mn
Sep 30, 2019 11.29 Mn
Jun 30, 2019 1.12 Mn
Mar 31, 2019 1.12 Mn
Dec 31, 2018 1.12 Mn
Sep 30, 2018 1.12 Mn
Jun 30, 2018 12.90 Mn
Mar 31, 2018 13.52 Mn
Dec 31, 2017 14.09 Mn
Sep 30, 2017 14.63 Mn
Jun 30, 2017 15.16 Mn